End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
42.92 CNY | +3.17% | -1.17% | -41.01% |
Apr. 17 | Interest Rate Outlooks Quell Asian Stock Markets | MT |
Apr. 11 | Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-41.01% | 16.21B | A- | ||
-2.00% | 103B | B+ | ||
+0.69% | 95.71B | B+ | ||
+1.69% | 22.02B | B | ||
-17.14% | 20.9B | B+ | ||
-9.30% | 17.85B | A- | ||
-14.89% | 15.52B | B | ||
+3.39% | 13.86B | C+ | ||
+35.26% | 12.04B | C+ | ||
-25.39% | 8.08B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603259 Stock
- Ratings WuXi AppTec Co., Ltd.